Literature DB >> 19587643

Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

M Anthony1, K Romero, D C Malone, L E Hines, L Higgins, R L Woosley.   

Abstract

Interactions of warfarin with other drugs or substances can pose a serious problem. We assessed three drug information compendia-Clinical Pharmacology, ePocrates, and Micromedex-and the warfarin sodium (Coumadin) product label (August 2007) approved by the US Food and Drug Administration for listings of interactions between warfarin and drugs, biologics, foods, and dietary supplements. The drug information compendia and warfarin label differed greatly as to the total number of substances that interact with warfarin. Of a total of 648 entries from the four sources, only 50 were common to all the sources. The types of substances listed as interacting with warfarin were entire classes of drugs, individual drugs, and combinations; biologics; dietary supplements; foods; alcohol; and tobacco. These sources were then examined for classification by severity of interaction and the underlying evidence base. This study provides evidence that there is little concordance among commonly used drug compendia and product labels with respect to interactions involving warfarin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587643     DOI: 10.1038/clpt.2009.95

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Warfarin: its highs and lows.

Authors:  Zack Dumont; Merunka Mordasiewicz; Lynette Kosar; Brenda Schuster
Journal:  Can Fam Physician       Date:  2013-08       Impact factor: 3.275

3.  Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study.

Authors:  Jill C Chappell; Gemma Dickinson; Malcolm I Mitchell; Harry Haber; Yan Jin; Evelyn D Lobo
Journal:  Eur J Clin Pharmacol       Date:  2011-09-01       Impact factor: 2.953

4.  Real-time and Label-free Bio-sensing of Molecular Interactions by Surface Plasmon Resonance: A Laboratory Medicine Perspective.

Authors:  Erik Helmerhorst; David J Chandler; Matt Nussio; Cyril D Mamotte
Journal:  Clin Biochem Rev       Date:  2012-11

5.  Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.

Authors:  L Gschwind; V Rollason; C Lovis; F Boehlen; P Bonnabry; P Dayer; J A Desmeules
Journal:  Eur J Clin Pharmacol       Date:  2012-08-19       Impact factor: 2.953

6.  Agreement among four drug information sources for the occurrence of warfarin drug interactions in Brazilian heart disease patients with a high prevalence of Trypanosoma cruzi infection.

Authors:  Maria A P Martins; Daniel D Ribeiro; Vandack A Nobre; Fabiana R Pereira; Cibele C César; Manoel O C Rocha; Antonio L P Ribeiro
Journal:  Eur J Clin Pharmacol       Date:  2012-09-28       Impact factor: 2.953

7.  Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources.

Authors:  Maria A P Martins; Paula P S Carlos; Daniel D Ribeiro; Vandack A Nobre; Cibele C César; Manoel O C Rocha; Antonio L P Ribeiro
Journal:  Eur J Clin Pharmacol       Date:  2011-06-24       Impact factor: 2.953

8.  The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype.

Authors:  John Maddison; Andrew A Somogyi; Berit P Jensen; Heather M James; Melanie Gentgall; Paul E Rolan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 9.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 10.  Assessing cardiovascular drug safety for clinical decision-making.

Authors:  Raymond L Woosley; Klaus Romero
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.